SK bioscience Co.,Ltd. (KRX:302440)
39,100
-50 (-0.13%)
Apr 18, 2025, 3:30 PM KST
SK bioscience Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 312,702 | 127,026 | 225,287 | 98,028 |
Short-Term Investments | 233,542 | 275,300 | 5,300 | -0 |
Trading Asset Securities | 611,864 | 871,816 | 1,250,218 | 1,547,635 |
Cash & Short-Term Investments | 1,158,108 | 1,274,141 | 1,480,806 | 1,645,663 |
Cash Growth | -9.11% | -13.96% | -10.02% | - |
Accounts Receivable | 94,462 | 12,928 | 39,585 | 38,006 |
Other Receivables | 93,934 | 9,414 | 50,076 | 10,129 |
Receivables | 188,396 | 22,342 | 89,661 | 48,135 |
Inventory | 211,126 | 80,649 | 187,406 | 135,046 |
Prepaid Expenses | 5,748 | 1,613 | 1,649 | 1,407 |
Other Current Assets | 13,295 | 4,224 | 24,173 | 7,554 |
Total Current Assets | 1,576,673 | 1,382,969 | 1,783,694 | 1,837,804 |
Property, Plant & Equipment | 982,607 | 315,923 | 293,057 | 220,983 |
Long-Term Investments | 22,357 | 42,729 | 1,500 | 21,610 |
Goodwill | 57,436 | - | - | - |
Other Intangible Assets | 56,084 | 14,178 | 6,299 | 3,973 |
Long-Term Deferred Tax Assets | 108,135 | 59,219 | 21,370 | 10,242 |
Long-Term Deferred Charges | 11,027 | 8,281 | 11,882 | 13,088 |
Other Long-Term Assets | 29,277 | 29,140 | 24,129 | 2,422 |
Total Assets | 2,843,596 | 1,852,439 | 2,141,931 | 2,110,123 |
Accounts Payable | 17,818 | 3,370 | 11,053 | 63,812 |
Accrued Expenses | 54,298 | 19,716 | 30,242 | 26,322 |
Short-Term Debt | - | - | 45,550 | 11,671 |
Current Portion of Long-Term Debt | - | - | 38,008 | 47,978 |
Current Portion of Leases | 6,957 | 8,137 | 12,235 | 2,309 |
Current Income Taxes Payable | 6,994 | - | 20,216 | 101,486 |
Other Current Liabilities | 224,523 | 104,397 | 222,733 | 206,374 |
Total Current Liabilities | 310,589 | 135,620 | 380,037 | 459,952 |
Long-Term Debt | 383,331 | - | - | 35,503 |
Long-Term Leases | 2,526 | 12,436 | 17,543 | 8,775 |
Long-Term Deferred Tax Liabilities | 71,960 | - | - | - |
Other Long-Term Liabilities | 52,737 | 527.84 | 2,649 | 335.24 |
Total Liabilities | 821,144 | 148,584 | 400,229 | 508,811 |
Common Stock | 39,174 | 38,414 | 38,392 | 38,250 |
Additional Paid-In Capital | 1,235,376 | 1,160,456 | 1,160,008 | 1,157,064 |
Retained Earnings | 499,757 | 549,421 | 533,378 | 405,305 |
Comprehensive Income & Other | 28,258 | -44,435 | 9,924 | 692.92 |
Total Common Equity | 1,802,565 | 1,703,855 | 1,741,702 | 1,601,312 |
Minority Interest | 219,887 | - | - | - |
Shareholders' Equity | 2,022,452 | 1,703,855 | 1,741,702 | 1,601,312 |
Total Liabilities & Equity | 2,843,596 | 1,852,439 | 2,141,931 | 2,110,123 |
Total Debt | 392,814 | 20,574 | 113,336 | 106,236 |
Net Cash (Debt) | 765,294 | 1,253,568 | 1,367,469 | 1,539,428 |
Net Cash Growth | -38.95% | -8.33% | -11.17% | - |
Net Cash Per Share | 9912.96 | 16277.20 | 17754.39 | 20850.38 |
Filing Date Shares Outstanding | 78.35 | 76.83 | 76.78 | 76.5 |
Total Common Shares Outstanding | 78.35 | 76.83 | 76.78 | 76.5 |
Working Capital | 1,266,083 | 1,247,350 | 1,403,657 | 1,377,852 |
Book Value Per Share | 23007.37 | 22177.60 | 22683.12 | 20932.18 |
Tangible Book Value | 1,689,045 | 1,689,678 | 1,735,403 | 1,597,339 |
Tangible Book Value Per Share | 21558.43 | 21993.06 | 22601.09 | 20880.24 |
Land | 71,307 | 45,280 | 45,270 | 9,949 |
Buildings | 425,887 | 124,315 | 127,741 | 119,990 |
Machinery | 174,922 | 55,879 | 53,141 | 51,037 |
Construction In Progress | 231,274 | 65,638 | 33,153 | 25,884 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.